Therapy of neurologic disorders in the elderly.
D000368:Aged; D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000188:drug therapy*; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use; D002230:Carbidopa / Q000009:adverse effects / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004347:Drug Interactions; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D014282:Trihexyphenidyl / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D010276:Parasympatholytics; D001971:Bromocriptine; D007980:Levodopa; D014282:Trihexyphenidyl; D003907:Dexamethasone; D006493:Heparin; D000547:Amantadine; D002230:Carbidopa